2023
In Vivo Imaging and Kinetic Modeling of Novel Glycogen Synthase Kinase-3 Radiotracers [11C]OCM-44 and [18F]OCM-50 in Non-Human Primates
Smart K, Zheng M, Holden D, Felchner Z, Zhang L, Han Y, Ropchan J, Carson R, Vasdev N, Huang Y. In Vivo Imaging and Kinetic Modeling of Novel Glycogen Synthase Kinase-3 Radiotracers [11C]OCM-44 and [18F]OCM-50 in Non-Human Primates. Pharmaceuticals 2023, 16: 194. PMID: 37259346, PMCID: PMC9959234, DOI: 10.3390/ph16020194.Peer-Reviewed Original ResearchPositron emission tomographyNon-human primatesMetabolite-corrected arterial input functionML/Free fractionWarrants further evaluationPotential therapeutic targetGood brain uptakeAdult rhesus macaquesPlasma free fractionArterial blood samplingGray matter regionsTwo-tissue compartment modelBrain uptakeRegional time-activity curvesBlood samplingPsychiatric disordersPET scansTherapeutic targetTime-activity curvesGray matterBrain regionsEmission tomographyFurther evaluationArterial input function
2019
Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET
Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 2254-2264. PMID: 31744389, PMCID: PMC7585925, DOI: 10.1177/0271678x19886316.Peer-Reviewed Original ResearchConceptsEffects of ketamineKetamine infusionGlutamate transmissionMetabotropic glutamate receptor 5Ketamine-induced effectsKetamine-induced changesGlutamate receptor 5Promising treatment targetDrug challenge studiesTwo-tissue compartment modelMGluR5 radioligandBlood pressureMGluR5 availabilityBaseline scanOutcome measuresHealthy subjectsHeart ratePsychiatric disordersReceptor 5Modulatory effectsMGluR5Treatment targetsChallenge studiesArterial input functionChallenge paradigm
2015
Test–retest reproducibility of the metabotropic glutamate receptor 5 ligand [18F]FPEB with bolus plus constant infusion in humans
Park E, Sullivan JM, Planeta B, Gallezot JD, Lim K, Lin SF, Ropchan J, McCarthy TJ, Ding YS, Morris ED, Williams WA, Huang Y, Carson RE. Test–retest reproducibility of the metabotropic glutamate receptor 5 ligand [18F]FPEB with bolus plus constant infusion in humans. European Journal Of Nuclear Medicine And Molecular Imaging 2015, 42: 1530-1541. PMID: 26044120, PMCID: PMC5467218, DOI: 10.1007/s00259-015-3094-6.Peer-Reviewed Original ResearchConceptsVolume of distributionAbsolute test-retest variabilityCerebellar white matterTest-retest reproducibilityMetabotropic glutamate receptor 5Venous blood measurementsGlutamate receptor 5Healthy male subjectsPromising PET radioligandArterial blood concentrationPET imaging tracerTest-retest variabilityTwo-tissue compartment modelRegional BPNDVenous bloodBlood concentrationsArterial bloodReceptor 5Constant infusionMale subjectsWhite matterBlood measurementsGray matterNeuropsychiatric diseasesPET radioligand
2000
PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635
Carson R, Lang L, Watabe H, Der M, Adams H, Jagoda E, Herscovitch P, Eckelman W. PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nuclear Medicine And Biology 2000, 27: 493-497. PMID: 10962257, DOI: 10.1016/s0969-8051(00)00118-9.Peer-Reviewed Original Research